These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32827835)

  • 21. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.
    Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A
    Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
    Lipkind HS; Vazquez-Benitez G; Nordin JD; Romitti PA; Naleway AL; Klein NP; Hechter RC; Jackson ML; Hambidge SJ; Lee GM; Sukumaran L; Kharbanda EO
    Obstet Gynecol; 2017 Sep; 130(3):599-608. PubMed ID: 28796684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.
    Zhao C; Zhao Y; Li J; Li M; Su Y; Mi X; La Tu SY; Shen D; Ren L; Li Y; Wang L; Wei L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052700. PubMed ID: 35358015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
    J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and Safety of a 9-Valent HPV Vaccine.
    Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A
    Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
    Murata S; Takeuchi Y; Yamanaka K; Hayakawa J; Yoshida M; Yokokawa R; Wakana A; Sawata M; Tanaka Y
    Jpn J Infect Dis; 2019 Sep; 72(5):299-305. PubMed ID: 31155600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
    Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
    Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
    Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization.
    Ackerson B; Hechter R; Sidell M; Sy LS; Slezak J; Chao C; Patel N; Tseng HF; Jacobsen S
    Vaccine; 2017 Feb; 35(6):897-902. PubMed ID: 28094077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy.
    Kharbanda EO; Vazquez-Benitez G; Lipkind HS; Sheth SS; Zhu J; Naleway AL; Klein NP; Hechter R; Daley MF; Donahue JG; Jackson ML; Kawai AT; Sukumaran L; Nordin JD
    Obstet Gynecol; 2018 Jul; 132(1):35-44. PubMed ID: 29889760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
    Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
    Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States.
    Gee J; Weinbaum C; Sukumaran L; Markowitz LE
    Hum Vaccin Immunother; 2016 Jun; 12(6):1406-17. PubMed ID: 27029786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.
    Widdice LE; Unger ER; Panicker G; Hoagland R; Callahan ST; Jackson LA; Berry AA; Kotloff K; Frey SE; Harrison CJ; Pahud BA; Edwards KM; Mulligan MJ; Sudman J; Bernstein DI
    Vaccine; 2018 Feb; 36(6):881-889. PubMed ID: 29306506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post Marketing Surveillance Study of 2nd Dose Quadrivalent Human Papilloma Virus Vaccine in Elementary School Children in Jakarta, Indonesia: Safety Result and Implementation of School-Based HPV Immunization Program.
    Satari HI; Sundoro J; Andrijono A; Hadinegoro SR; Syafriyal S; Tandy G; Karolina S
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):869-875. PubMed ID: 30912406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.